Humanwell Healthcare Secures Approval for $400M Ibuprofen Suspension and Files First-to-File Application for $700M Loxoprofen Sodium Patch
Johnson & Johnson
Medical Device R&D and Manufacturer
Daiichi - Sankyo
Pharmaceutical Development, Production, Sales, and Consulting Service Provider
Recently,Renfu PharmaceuticalsGood news keeps coming. On December 9,Renfu PharmaceuticalsSubsidiaryWuhan Jiulong PharmaceuticalTheCategory 4Generic DrugIbuprofen SuspensionApproved by NMPA for marketing and deemed to have passed the evaluation; today,Renfu PharmaceuticalCategory 4 generic drugs submitted for approvalLoxoprofen Sodium PatchThe listing application has been officially accepted by the CDE, and there is currently no generic version of this product approved in China.
Source of Screenshot: Mosana Pharmaceuticals China Drug Evaluation Database (For data inquiries, contact Mosana)
Securing Over 400 Million Yuan in Major Varieties, Renfu's In-Hospital Market Ranks Steadily in the Top Three
Ibuprofen SuspensionIt is a non-steroidal anti-inflammatory drug that exerts antipyretic, analgesic, and anti-inflammatory effects by inhibiting prostaglandin synthesis. It is mainly used for fever and headaches caused by colds or flu in children, as well as relieving mild to moderate pain such as joint pain, toothache, and muscle pain. According to the Maxent Pharmaceuticals database, the total sales of this product in the Chinese hospital market exceeded 400 million yuan in 2024.
Screenshot source: Mosentropy Medicine All-Terminal Hospital Sales Database (Check data, find Mo Entropy)
In terms of the competitive landscape analysis, in the 2024 hospital market, Johnson & Johnson secured the top position within hospitals with a 53.22% market share, followed by Tianda Pharmaceuticals with 17.01%, and Renfu Pharmaceutical occupying third place with 8.68%.
Screenshot source: Mosun Medicine All-Terminal Hospital Sales Database (For data inquiries, contact Mosun)
As of now, 33 pharmaceutical companies in China have obtainedIbuprofen SuspensionThe production batch document. Among them,Wuhan Jiulong Pharmaceutical、Chengdu Better Pharma、Shandong Shengdi Pharmaceutical、Jiangsu Wango PharmaceuticalsA total of 23 pharmaceutical companies have not only been approved for production but also successfully passed the consistency evaluation. Notably, Hubei Duorui Pharmaceutical became the first company in this category to pass the evaluation.
Over 700 Million Yuan Product, Humanwell Healthcare Enters the First Generic Market
Loxoprofen Sodium PatchThe original research company isLEAD CHEMICALCO.LTD, sold by Daiichi - Sankyo. This variety is a non-steroidal anti-inflammatory drug.（NSAID）, exerts anti-inflammatory, analgesic, and antipyretic effects by inhibiting prostaglandin synthesis. It is mainly used to relieve swelling and pain caused by osteoarthritis, muscle pain, and trauma. According to the Moxuan Medical Database, the total sales of this product in all-terminal hospitals in China exceeded 700 million yuan in 2024, with a year-on-year increase of 32.93%. In the first half of 2025, sales exceeded 400 million yuan, with a year-on-year increase of 26.86%.
Screenshot source: Mosun Pharmaceuticals All-Terminal Hospital Sales Database (For data inquiries, contact Mosun)
Currently,Loxoprofen Sodium PatchesIt has been approved for marketing in China as an original research drug and included in the Class B National Medical Insurance Catalog. Various formulations of Loxoprofen Sodium, such as gel patches, oral solutions, granules, tablets, and capsules, have already been marketed in China.
In terms of generic drug layout,Loxoprofen Sodium PatchesIn China, 21 pharmaceutical companies, including Beijing Fuyuan Pharmaceutical, Sichuan Kelun Pharmaceutical, Zhejiang Saimer Pharmaceutical, and Beijing Baiao Pharmaceutical, have submitted generic drug registration applications, all of which are currently under review.
Screenshot source: Mosentropy China Drug Evaluation Database (For data inquiries, contact Mosentropy)
As of now,Renfu Pharmaceutical(Including subsidiaries)More Than 20 Generic Drugs Under Review. In the field of generic drugs, Renfu Pharmaceuticals(Including Subsidiaries)Currently, more than 100 varieties have been approved and passed the evaluation, among whichInjectable Remifentanil Hydrochloride、Hydromorphone Hydrochloride Injection、Tapentadol Hydrochloride TabletsThe first 25 products passed the evaluation.
Source of Information:
1. CDE Official Website
2. Moshang Pharmaceutical Database
END
This article is original. Please leave a message to obtain authorization for reprint.
More RecentlyMoxie ConsultingPopular Report, Scan the QR Code Below to Claim
Contact us to experience more professional services from Mosen Pharmaceuticals. | ||||
WillDiscussion CombinedWork | GardenDistrict TakeWu | Database Consultation | Customization Service | Media Cooperation |
ClickImage Above, you can start the Mosuan chemical data query
